Chemomab Therapeutics Files 6-K with Prospectus Supplement Details
Ticker: CMMB · Form: 6-K · Filed: Mar 20, 2025 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: prospectus-supplement, sales-agreement, legal-opinion
TL;DR
Chemomab filed a 6-K detailing a Nov 2024 prospectus supplement under a Roth Capital sales agreement.
AI Summary
Chemomab Therapeutics Ltd. filed a Form 6-K on March 20, 2025, reporting on a prospectus supplement filed on November 15, 2024, under a Sales Agreement with Roth Capital Partners, LLC, dated October 16, 2023. The filing also includes an opinion from Meitar | Law Offices.
Why It Matters
This filing provides an update on Chemomab's financing activities and legal counsel, which can be important for investors tracking the company's financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine filing providing information about previous agreements and legal opinions, not indicating new significant risks.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Registrant
- Roth Capital Partners, LLC (company) — Underwriter in Sales Agreement
- Meitar | Law Offices (company) — Legal Counsel
- November 15, 2024 (date) — Date of prospectus supplement filing
- October 16, 2023 (date) — Date of Sales Agreement
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K filed on March 20, 2025, reports on a prospectus supplement filed on November 15, 2024, under a Sales Agreement with Roth Capital Partners, LLC, and includes an opinion from Meitar | Law Offices.
When was the Sales Agreement with Roth Capital Partners, LLC dated?
The Sales Agreement with Roth Capital Partners, LLC was dated October 16, 2023.
Who provided the legal opinion included in this filing?
Meitar | Law Offices provided the legal opinion.
What is the former name of Chemomab Therapeutics Ltd. mentioned in the filing?
The filing mentions that Chemomab Therapeutics Ltd. was formerly known as Anchiano Therapeutics Ltd. (name change effective September 6, 2018) and BioCancell Ltd. (name change effective November 4, 2011).
What is Chemomab Therapeutics Ltd.'s primary business sector?
Chemomab Therapeutics Ltd. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 regarding Chemomab Therapeutics Ltd. (CMMB).